The production of chiral amines through
asymmetric synthesis using
amine transaminase (ATA) has the potential for high yields in an efficient
single-step process. Integrating in situ membrane
extraction with this biocatalytic chiral amine production process
has been demonstrated to reach higher yields by shifting the equilibrium
position through product recovery. To date, however, it is unclear
whether the in situ product recovery strategy is
economically viable. This study carried out a techno-economic assessment
to understand the main drivers of the manufacturing costs and to set
quantitative development targets. The chiral amine products under
study are (R)-(+)- or (S)-(−)-α-methylbenzylamine
(MBA) and sitagliptin. Their manufacturing costs were quantified and
benchmarked to three alternative production pathways. The results
yield an MBA manufacturing cost of €17.8/mol for the integrated
process with membrane extraction, which is lower than the cost for
the benchmark process using an ion-exchange resin (€23.4/mol).
The sitagliptin manufacturing cost is estimated to be €30.9/mol,
which is €1.6/mol and €4.6/mol less than the benchmark
process with engineered transaminase and the rhodium-catalyzed process,
respectively. On the basis of the outcomes of sensitivity analyses,
development targets were set for the membrane flux and selectivity
and the product concentration, which are the key parameters that influence
the manufacturing cost related to the membrane.